1.61
+0.025(+1.58%)
Currency In USD
| Previous Close | 1.59 |
| Open | 1.59 |
| Day High | 1.7 |
| Day Low | 1.57 |
| 52-Week High | 28.8 |
| 52-Week Low | 1.5 |
| Volume | 36,235 |
| Average Volume | 81,307 |
| Market Cap | 11.85M |
| PE | -0.05 |
| EPS | -32.7 |
| Moving Average 50 Days | 2.01 |
| Moving Average 200 Days | 4.7 |
| Change | 0.03 |
If you invested $1000 in Eterna Therapeutics Inc. (ERNA) 10 years ago, it would be worth $0.28 as of August 18, 2025 at a share price of $1.61. Whereas If you bought $1000 worth of Eterna Therapeutics Inc. (ERNA) shares 5 years ago, it would be worth $1.06 as of August 18, 2025 at a share price of $1.61.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Ernexa Therapeutics Regains Compliance with Nasdaq Listing Requirements
GlobeNewswire Inc.
Jul 09, 2025 12:30 PM GMT
CAMBRIDGE, Mass., July 09, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today announced that it has regained compliance with Nasdaq f
Ernexa Therapeutics Expands Advisory Board to Form Integrated Scientific and Medical Advisory Board as it Prepares for Clinical Development
GlobeNewswire Inc.
Jun 25, 2025 12:30 PM GMT
Addition of Dr. Amir Jazaeri and Dr. Anna Jonsson Reflects Ernexa’s Strategic Focus on Ovarian Cancer and Autoimmune Disease ProgramsCAMBRIDGE, Mass., June 25, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell
Ernexa Therapeutics Secures $6 Million in Second Closing Under Securities Purchase Agreement
GlobeNewswire Inc.
Jun 24, 2025 12:30 PM GMT
Stockholder-approved financing brings total gross proceeds to $7.1 million; funds to support working capital initiativesCAMBRIDGE, Mass., June 24, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for